Please select the option that best describes you:
When starting a patient on a tyrosine kinase inhibitor for chronic phase CML, which drug do you choose upfront?
Imatinib, or a second-generation TKI? Are there specific factors that make you choose one over the other?
Answer from: Medical Oncologist at Community Practice
Randomized clinical trials with nilotinib and dasatinib versus imatinib have shown improved rates of molecular response for the second-generation TKIs:https://www.ncbi.nlm.nih.gov/pubmed/24311723https://www.ncbi.nlm.nih.gov/pubmed/20525993https://www.ncbi.nlm.nih.gov/pubmed/20525995Improved response...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I start with nilotinib. I think it is well tolerated and that molecular responses are deeper and the chance of cure is greater.